Authors: Kauff, ND Scheuer, L Robson, ME Glogowski, E Kelly, B Barakat, R Heerdt, A Borgen, PI Davis, JG Offit, K

Citation: Nd. Kauff et al., Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations, GENET MED, 3(6), 2001, pp. 422-425

Authors: Klauber-DeMore, N Tan, LK Liberman, L Kaptain, S Fey, J Borgen, P Heerdt, A Montgomery, L Paglia, M Petrek, JA Cody, HS Van Zee, KJ

Citation: N. Klauber-demore et al., Sentinel lymph node biopsy: Is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?, ANN SURG O, 7(9), 2000, pp. 636-642

Authors: Liberman, L Ernberg, LA Heerdt, A Zakowski, MF Morris, EA LaTrenta, LR Abramson, AF Dershaw, DD

Citation: L. Liberman et al., Palpable breast masses: Is there a role for percutaneous imaging-guided core biopsy?, AM J ROENTG, 175(3), 2000, pp. 779-787

Authors: Robson, M Levin, D Federici, M Satagopan, J Bogolminy, F Heerdt, A Borgen, P McCormick, B Hudis, C Norton, L Boyd, J Offit, K

Citation: M. Robson et al., Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations, J NAT CANC, 91(24), 1999, pp. 2112-2117